Osiris Therapeutics (OSIR) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Osiris Therapeutics (OSIR) Misses Q2 EPS by 3c

Osiris Therapeutics (OSIR) PT Raised to $25 at Brean Capital; Grafix Positioned Well for Accelerated Growth

August 6, 2015 8:26 AM EDT

Brean Capital analyst Difei Yang reiterated a Buy rating and raised the price target on Osiris Therapeutics (NASDAQ: OSIR) to $25.00 (from $19.00), saying Grafix is positioned well for accelerated growth.

Yang commented, "Q2 met expectations on revenue but missed on... More